DNAJA1 Antibody [J3K12]

Katalog-Nr. F4809

Drucken

Biologische Beschreibung

Spezifität DNAJA1 Antibody [J3K12] weist endogene Spiegel des gesamten DNAJA1-Proteins nach.
Hintergrund DNAJA1 (DnaJ-Homolog-Subfamilie-A-Mitglied 1) ist ein zytosolisches Hsp40-Co-Chaperon vom Typ I, das für die Proteostase und Stresssignalgebung unerlässlich ist. Es verfügt über eine N-terminale J-Domäne (Aminosäurereste 4–70, mit einem HPD-Motiv an His33-Pro34-Asp35, das für die Hsp70-ATPase-Stimulation entscheidend ist), eine C4-Zinkfingerdomäne (aa 78–115, die acht Cysteine enthält, die zwei Zn²⁺-Ionen koordinieren, um hydrophobe Bereiche an Client-Proteinen zu untersuchen), einen Glycin/Phenylalanin-reichen flexiblen Linker (aa 116–165) und eine C-terminale Substratbindungsdomäne (aa 166–397), die aus gestapelten β-Faltblättern und α-Helices besteht, sowie ein farnesyliertes CTIL355–358-Motiv zur dynamischen Verankerung am ER oder an der Plasmamembran. Im Hsp70-Chaperonzyklus dockt die α-Helix II der J-Domäne an die Nukleotidbindungsdomäne von Hsp70 an, beschleunigt die ATP-Hydrolyse um über das 1000-Fache und fängt Substrate im ADP-gebundenen Zustand ein. Die Zinkfinger liefern Clients wie das konformationell mutierte p53 (wobei DNAJA1 an die mutp53-Kerndomäne bindet, um die CHIP-E3-Ubiquitinierung an Lys620 sterisch zu blockieren, was onkogene Konformer stabilisiert, die die Invasion von Bauchspeicheldrüsen- und Gallengangskarzinomen über Cdc42/Rac1-vermittelte Filopodien vorantreiben), CFTR ΔF508 (das Triage für die ER-Retention und Retrotranslokation über Hsc70 steuert), tau-Fibrillen (die die Hsp104-unabhängige Disaggregation erleichtern) und nukleäre Importkomplexe von Influenza PB2/PA. DNAJA1 hemmt auch die JNK/c-Jun-Hyperaktivierung unter oxidativem und ER-Stress, indem es die Hsc70-vermittelte SAPK-Sequestrierung fördert und dadurch die BAX-vermittelte Permeabilisierung der mitochondrialen äußeren Membran und Apoptose verhindert. Zusätzlich moduliert es die PolyQ-htt-Aggregation in Huntington-Modellen und den hERG-Kanaltransport. Eine DNAJA1-Downregulation in PDAC-Tumoren erhöht paradoxerweise die mutp53-Persistenz und das Tumorwachstum, wodurch diese Tumoren für J-Domänen-Inhibitoren (wie A11, das Y7/K44/Q47 angreift, um die mutp53-Interaktion zu stören und deren proteasomalen Abbau zu fördern) sensibilisiert werden.

Nutzungsinformationen

Anwendung WB, FCM Verdünnung
WB FCM
1:10000 - 1:50000 1:10 - 1:100
Reaktivität Human
Quelle Rabbit Monoclonal Antibody MW 45 kDa
Lagerpuffer PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
Lagerung
(Ab dem Datum des Erhalts)
-20°C (avoid freeze-thaw cycles), 2 years
WB
Experimental Protocol:
 
Sample preparation
1. Tissue: Lyse the tissue sample by adding an appropriate volume of ice-cold RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail),and homogenize the tissue at a low temperature.
2. Adherent cell: Aspirate the culture medium and wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail) and put the sample on ice for 5 min.
3. Suspension cell: Transfer the culture medium to a pre-cooled centrifuge tube. Centrifuge and aspirate the supernatant. Wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail) and put the sample on ice for 5 min.
4. Place the lysate into a pre-cooled microcentrifuge tube. Centrifuge at 4°C for 15 min. Collect the supernatant;
5. Remove a small volume of lysate to determine the protein concentration;
6. Combine the lysate with protein loading buffer. Boil 20 µL sample under 95-100°C for 5 min. Centrifuge for 5 min after cool down on ice.
 
Electrophoretic separation
1. According to the concentration of extracted protein, load appropriate amount of protein sample and marker onto SDS-PAGE gels for electrophoresis. Recommended separating gel (lower gel) concentration: 10%. Reference Table for Selecting SDS-PAGE Separation Gel Concentrations
2. Power up 80V for 30 minutes. Then the power supply is adjusted (110 V~150 V), the Marker is observed, and the electrophoresis can be stopped when the indicator band of the predyed protein Marker where the protein is located is properly separated. (Note that the current should not be too large when electrophoresis, too large current (more than 150 mA) will cause the temperature to rise, affecting the result of running glue. If high currents cannot be avoided, an ice bath can be used to cool the bath.)
 
Transfer membrane
1. Take out the converter, soak the clip and consumables in the pre-cooled converter;
2. Activate PVDF membrane with methanol for 1 min and rinse with transfer buffer;
3. Install it in the order of "black edge of clip - sponge - filter paper - filter paper - glue -PVDF membrane - filter paper - filter paper - sponge - white edge of clip";
4. The protein was electrotransferred to PVDF membrane. ( 0.45 µm PVDF membrane is recommended ) Reference Table for Selecting PVDF Membrane Pore Size Specifications
Recommended conditions for wet transfer: 200 mA, 120 min.
( Note that the transfer conditions can be adjusted according to the protein size. For high-molecular-weight proteins, a higher current and longer transfer time are recommended. However, ensure that the transfer tank remains at a low temperature to prevent gel melting.)
 
Block
1. After electrotransfer, wash the film with TBST at room temperature for 5 minutes;
2. Incubate the film in the blocking solution for 1 hour at room temperature;
3. Wash the film with TBST for 3 times, 5 minutes each time.
 
Antibody incubation
1. Use 5% skim milk powder to prepare the primary antibody working liquid (recommended dilution ratio for primary antibody 1:10000), gently shake and incubate with the film at 4°C overnight;
2. Wash the film with TBST 3 times, 5 minutes each time;
3. Add the secondary antibody to the blocking solution and incubate with the film gently at room temperature for 1 hour;
4. After incubation, wash the film with TBST 3 times for 5 minutes each time.
 
Antibody staining
1. Add the prepared ECL luminescent substrate (or select other color developing substrate according to the second antibody) and mix evenly;
2. Incubate with the film for 1 minute, remove excess substrate (keep the film moist), wrap with plastic film, and expose in the imaging system.

Referenzen

  • https://pubmed.ncbi.nlm.nih.gov/24512202/
  • https://pubmed.ncbi.nlm.nih.gov/33229560/

Anwendungsdaten

WB

Validiert von Selleck

  • F4809-wb
    Lane 1: HepG2, Lane 2: SK-BR-3, Lane 3: Jurkat, Lane 4: Raji